01
Cash & equivalents increased 23.1%
Cash & equivalents changed +23.1% from the comparable as-filed period.
$16.4M→$20.2MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTPharmaCyte Biotech, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +23.1% from the comparable as-filed period.
Net income changed +124.5% from the comparable as-filed period.
Operating income changed -120.6% from the comparable as-filed period.
Research & development changed -21.2% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
PMCB · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001683168-26-005836SEC ↗4/AJul 17, 2026Period Mar 31, 20260001683168-26-005622SEC ↗4/AJul 17, 2026Period Mar 31, 20260001683168-26-005621SEC ↗4/AJul 17, 2026Period Mar 31, 20260001683168-26-005620SEC ↗4/AJul 17, 2026Period Mar 31, 20260001683168-26-005619SEC ↗4Apr 2, 2026Period Mar 31, 20260001683168-26-002633SEC ↗4Apr 2, 2026Period Mar 31, 20260001683168-26-002632SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Mar 31, 2026Filed Jul 17, 2026 | WALKER WAYNE REMELLDirector | OtherDirect · amended | 0 | — | — | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Revenue changed +0.0% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-04-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001683168-26-002631